Brain Enzyme Elevation Emerges as Possible Alzheimer's Disease Indicator

Research from Spanish scientists has identified elevated levels of the enzyme meprin-β in both brain tissue and cerebrospinal fluid of Alzheimer's patients, suggesting it could serve as a new biomarker for the disease. Experiments demonstrated that exposure to beta-amyloid, the protein that accumulates in Alzheimer's brains, increases meprin-β levels, establishing a potential connection between disease progression and enzyme activity. The findings appear particularly significant in advanced stages of the disease, opening new avenues for understanding how multiple enzymes contribute to neurodegeneration.

Alzheimer's disease involves the progressive breakdown of brain proteins, particularly through the fragmentation of amyloid precursor protein into harmful beta-amyloid pieces. Scientists have traditionally concentrated on understanding BACE1, the primary enzyme responsible for this cleavage process. However, this Spanish research team discovered that meprin-β, a secondary enzyme capable of performing similar protein-cutting functions, also shows significant elevation in Alzheimer's patients—particularly those in more advanced disease stages.

The researchers employed sophisticated methodologies to reach their conclusions, including analysis of brain tissue samples classified by disease progression stages and laboratory experiments using human neurons derived from stem cells. When these cultured neurons were exposed to beta-amyloid, meprin-β levels rose substantially, demonstrating a potential causal relationship between disease hallmarks and enzyme activity rather than mere correlation.